Going against the flow: The impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis

New Zealand Medical Journal

Volumn 118, Issue 1223, 2005, Pages

  Grocott, Rachel ^a   Metcalfe, Scott ^b  

^a WELLINGTON HOSPITAL   (New Zealand)

^b Pharmaceutical Management Agency   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ARTICLE; AUSTRALIA; CHRONIC ARTHRITIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FINANCIAL MANAGEMENT; GASTROINTESTINAL SYMPTOM; GOVERNMENT; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH ECONOMICS; HEART INFARCTION; HUMAN; MEDICAL DECISION MAKING; META ANALYSIS; NEW ZEALAND; RISK BENEFIT ANALYSIS; STROKE; SYSTEMATIC REVIEW; THROMBOSIS; ARTHRITIS; COST BENEFIT ANALYSIS; DRUG APPROVAL; DRUG SCREENING; ECONOMICS; INTERNATIONAL COOPERATION; METHODOLOGY; PUBLIC HEALTH;

ARTHRITIS; COST-BENEFIT ANALYSIS; CYCLOOXYGENASE 2 INHIBITORS; DRUG APPROVAL; DRUG EVALUATION; HUMANS; INTERNATIONALITY; NATIONAL HEALTH PROGRAMS; NEW ZEALAND;

EID: 27744580149     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000 Sep 13;284(10):1247-55.
2. Bombardier C, Laine L, Reicin A, et al; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528.
3. Juni P, Rutjes AWS, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ 2002, 324: 1287-8. Available online. URL: http://bmj.bmjjournals.com/cgi/content/full/324/7349/1287 Accessed September 2005.
4. Gottlieb S. Researchers deny any attempt to mislead the public over JAMA article on arthritis drug. BMJ 2001;323:301.
5. Metcalfe S, Dougherty S, McNee W. Celebrex's relative gastrointestional safety is overstated. BMJ 2003. 326: 334-5. Available online. URL: http://bmj.com/cgi/content/full/326/7384/334 Accessed September 2005.
6. Graham DY. NSAIDs, Helicobacter pylori, and Pandora's Box. N Engl J Med. 2002;347:2162-4.
7. [No authors listed] Rofecoxib in rheumatoid arthritis: new indication. No better that other NSAIDS. Prescrire Int. 2003 Jun;12(65):89-90.
8. Therapeutics Initiative British Columbia. Therapeutics Letter 43. November / December 2001 & January 2002. COX-2 inhibitors update: Do journal publications tell the full story? Available online. URL: http://www.ti.ubc.ca/pages/letter53.htm Accessed September 2005.
9. Therapeutics Initiative British Columbia. Therapeutics Letter 39. January / February 2001. Selective COX-2 inhibitors: Are they safer NSAIDs? Available online. URL: http://www.ti.ubc.ca/pages/letter39.htm Accessed September 2005.
10. Wright JM. The double-edged sword of COX-2 selective NSAIDs. CMAJ. 2002 Nov 12;167(10):1131-7. Available online. URL: http://www.cmaj.ca/cgi/content/full/167/10/1131 Accessed September 2005.
11. Targum SL. Food and Drug Administration: cardiovascular safety review rofecoxib. 2001. Available online. URL: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b206cardio.pdf Accessed September 2005.
12. Bresalier RS, Sandler RS, Quan H, et al. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005 Mar 17;352(11):1092-102.
13. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005 Feb 5-11;365(9458):475-81.
14. Weatherall M, Aldington S, Shirtcliffe P, et al. COX-2 inhibitors - first, do no harm. N Z Med J. 2005 Mar 11;118(1211). URL: http://www.nzma.org.nz/journal/118-1211/1359/
15. Solomon SD, McMurray JJ, Pfeffer MA, et al; Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005 Mar 17;352(11):1071-80. Epub 2005 Feb 15.
16. Minutes of the 121st Medicines Adverse Reactions Committee meeting, 15th March 2005. Available online. URL: http://www.medsafe.govt.nz/profs/adverse/minutes121.htm Accessed September 2005.
17. PHARMAC Discussion Document. Celecoxib (Celebrex) and rofecoxib (Vioxx) - selective cox-2 inhibitors - for osteoarthritis and rheumatoid arthritis. February 2004. Available online. URL: http://www.pharmac.govt.nz/pdf/Cox2.pdf Accessed September 2005.
18. New Zealand Public Health and Disability Act 2000, Section 47 Objectives of Pharmac
19. Rafter N. Milne R. Jackson R. PHARMAC Technology Assessment Report No. 55 - Listing rofecoxib and celecoxib in the Pharmaceutical Schedule. 2003 (unpublished).
20. PHARMAC. Report of the Pharmaceutical Management Agency Limited for the year ended 30 June 2000. Presented to the House of Representatives pursuant to Section 44A of the Public Finance Act 1989. PHARMAC, 2000. Available online. URL: http://www.pharmac.govt.nz/pdf/Annual_Report_2000.pdf Accessed September 2005.
21. PHARMAC. Annual Report of the Pharmaceutical Management Agency for the year ended 30 June 2001. Presented to the House of Representatives pursuant to Section 44A of the Public Finance Act 1989. PHARMAC, 2001. Available online. URL: http://www.pharmac.govt.nz/pdf/AnnRep01.pdf Accessed September 2005.
22. PHARMAC. Annual Report of the Pharmaceutical Management Agency for the year ended 30 June 2002. Presented to the House of Representatives pursuant to Section 44A of the Public Finance Act 1989. PHARMAC, 2002. Available online. URL: http://www.pharmac.govt.nz/pdf/Annual%20Report%202002.pdf Accessed September 2005.
23. PHARMAC. Annual Report of the Pharmaceutical Management Agency for the year ended 30 June 2003. Presented to the House of Representatives pursuant to Section 44A of the Public Finance Act 1989. PHARMAC, 2003. Available online. URL: http://www.pharmac.govt.nz/pdf/ARep03.pdf Accessed September 2005.
24. PHARMAC. Annual Report of the Pharmaceutical Management Agency for the year ended 30 June 2004. Presented to the House of Representatives pursuant to Section 44A of the Public Finance Act 1989. PHARMAC, 2004. Available online. URL: http://www.pharmac.govt.nz/pdf/AR04.pdf Accessed September 2005.
25. Maetzel A. Krahn M. Naglie G. The cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis. Canadian Coordinating Office for Health Technology Assessment 2001. Technology Report No. 23. Available online. URL: http://www.ccohta.ca/ Accessed September 2005.
26. Spiegel B. Targownik L. Dulai G. Gralnek I. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Int Med 2003;138(10):795-806.
27. Cox ER. Motheral B. Mager D. Verification of a Decision Analytic Model Assumption Using Real-World Practice Data: Implications for the Cost Effectiveness of Cyclo-oxygenase 2 Inhibitors (COX-2s). Am J Managed Care 2003; 9(12):785-94
28. Medsafe media release. Stringent conditions for cox-2 inhibitors. April 2005. Available online. URL: http://www.medsafe.govt.nz/hot/media/2005/COX2April05.htm Accessed September 2005.
29. PHARMAC analysis of PBS services and cost data at http://www.hic.gov.au/statistics/dyn_pbs/forms/pbs_tabl.shtml (codes 8439E, 8440F, 8471W, 8472X, 8473Y, 8474B)
30. Dowden JS. Coax, COX and cola. Med J Aust. 2003 Oct 20;179(8):397-8.
31. Prescribing Practice Review 16. Cox-2 selective NSAIDs. National Prescribing Service Limited. 2001.
32. Therapeutic Goods Administration. Expanded information on cox-2 inhibitors for doctors and pharmacists. February 2005. Available online. URL: http://www.tga.gov.an/media/2005/050214_cox2.pdf Accessed September 2005.
33. European Medicines Agency. Public statement, European Medicines Agency announces regulatory action on cox-2 inhibitors. Available online. URL: http://www.emea.eu.int/pdfs/human/press/pr/6275705en.pdf Accessed September 2005.
34. European Medicines Agency. Press release, European Medicines Agency concludes action on cox-2 inhibitors. Available online. URL http://www.emea.eu.int/pdfs/human/press/pr/20776605en.pdf Accessed September 2005.
35. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004 Dec 4-10;364(9450):2021-9. Available online. URL: